The results showed that FAP+CAFs may impair the efficacy of anti-PD-1 therapy in gastric cancer mice, and that IL-31 blockade can partially restore treatment sensitivity, potentially by alleviating the immunosuppressive effects associated with FAP+CAFs [Figure 6A and B]. This evidence concerns the gene FAP and gastric cancer.